• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Adjuvant chemotherapy may potentially be avoided in breast cancer patients with lymph node-positive disease

byKassandra McFarlaneandSze Wah Samuel Chan
December 28, 2021
in Chronic Disease, Oncology
Reading Time: 2 mins read
Breast cancer collage of a calm woman in her fifties, a mammography machine, a cup of tea and a blank card
Share on FacebookShare on TwitterShare on LinkedIn

1. For postmenopausal women, invasive disease-free survival and distant relapse-free survival was similar between chemoendocrine therapy and endocrine-only therapy

2. For premenopausal women, distant relapse-free survival is greater in those receiving chemoendocrine therapy than endocrine-only therapy

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-positive breast cancer is associated with increased recurrence risk. Recurrence scores based on a 21-gene breast cancer assay are prognostic and used in node-negative patients to stratify the risk of recurrence and potentially avoid chemotherapy. This study explored the impact of adjuvant chemotherapy with endocrine therapy as opposed to endocrine-only therapy on invasive disease-free survival in women with hormone-receptor-positive, HER2-negative, node-positive breast cancer with recurrence scores of 25 or lower. Secondary outcomes included distant relapse-free survival. The women were separated into subgroups based on menopausal status (either pre-or post-menopausal). Invasive disease-free survival within postmenopausal women was not significantly different between chemoendocrine and endocrine-only treatment groups. Chemoendocrine therapy was more beneficial for invasive disease-free survival than endocrine-only therapy in the premenopausal subgroup. The benefit of chemotherapy did not increase with higher recurrence scores. The distant relapse-free survival was similar in postmenopausal women for both treatment groups, while it was greater for the chemoendocrine group than the endocrine-only group in premenopausal women. Limitations to this study include reduced power in the intention-to-treat analysis as a result of a greater-than-expected number of patients declining assigned treatment. Overall, adult female patients with hormone-receptor-positive, HER2-negative, node-positive breast cancer and recurrence scores ranging between 0 and 25 can safely avoid adjuvant chemotherapy.

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer

RELATED REPORTS

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma

FDA approvedFor breast cancer: Etcamah (camizestrant), Sep 4, 2026→

In-Depth [prospective cohort]: This multicentre, prospective cohort study was conducted out of 632 centres in 9 countries randomly allocated 5018 adult female patients with hormone-receptor-positive, HER2-negative, node-positive breast cancer and recurrence scores between 0-25 to receive either endocrine-only therapy or chemoendocrine therapy. Exclusion criteria included those with a recurrence score >25. Within each group, the women were split into those who were premenopausal and those who were postmenopausal. The primary outcome was the effect of adjuvant chemotherapy on invasive disease-free survival as well as the correlation of recurrence scores with chemotherapy benefits. Secondary outcomes included distant relapse-free survival. For the postmenopausal group, invasive disease-free survival in patients receiving endocrine therapy was 91.9%, and 91.3% in patients receiving chemoendocrine therapy (HR 1.02; (95% CI, 0.82-1.26)). In the premenopausal endocrine-only therapy group, the invasive disease-free survival was 89.0% and was 93.9% for those receiving chemoendocrine therapy (HR 0.60 (95% CI, 0.43-0.83)). The benefit of chemotherapy did not increase with higher recurrence scores. The postmenopausal treatment groups did not differ significantly in distant relapse-free survival (hazard ratio (HR), 1.05 (95% confidence interval (CI), 0.81-1.37). The premenopausal group receiving chemoendocrine treatment had a significantly higher distant relapse-free survival as compared to the endocrine-only group (HR 0.58 (95% CI, 0.39-0.87)).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adjuvant chemotherapyBreast Cancergene testing
Previous Post

Online mutual help for alcohol use recovery may have decreased during COVID-19 pandemic

Next Post

Higher levels of screen use associated with poorer mental health in Canadian children and youth during the COVID-19 pandemic

RelatedReports

A middle-aged woman looks thoughtfully at an abstract representation of cells and a statin pill, symbolizing breast cancer and medication usage.
Oncology

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

October 5, 2026
An illustration featuring a large intestine surrounded by various silhouettes of heads, representing demographics, alongside abstract elements.
Chronic Disease

Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma

September 18, 2026
Sleep disorders collage: an engraved pillow and rumpled sheet with a dark sleep mask, a paper crescent moon and a teal ribbon
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Breast cancer care collage: a calm woman in a turtleneck sweater beside a folded paper crane and a small white pill bottle
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Next Post

Higher levels of screen use associated with poorer mental health in Canadian children and youth during the COVID-19 pandemic

Prevalence of major depressive and anxiety disorders has increased during the COVID-19 pandemic

Vitamin D supplementation not supported to treat first-episode psychosis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.